论文部分内容阅读
贝凡洛尔(bevantolol)是一种新的β受体阻滞剂,对β_1受体有高度选择性作用,无内在拟交感活性,降低血管外周阻力。实验表明,贝凡洛尔体内外都能抑制异丙肾上腺素的变时性反应,对肾上腺素、酪胺、1,4-二甲基-4-哌嗪碘化物、颈动脉闭塞诱发麻醉犬心动过速有抑制作用。对豚鼠心房异丙肾上腺素反应的拮抗作用明显大于对支气管异丙肾上腺素反应。在狗,该药比心得安更能选择性阻断异丙肾上腺素的变时性反应。在人,每天服用本品200mg与每天用氨酰心安100mg产生相同的降低异丙肾上
Bevantolol is a new beta-blocker with a high degree of selectivity for the beta 1 -receptor with no intrinsic sympathomimetic activity and reduced peripheral vascular resistance. Experiments show that bevolta can inhibit isoproterenol in vitro and in vivo chronotropic response to epinephrine, tyramine, 1,4-dimethyl-4-piperazine iodide, carotid artery occlusion induced anesthesia dogs Tachycardia has inhibitory effect. The antagonism of atrial isoproterenol response in guinea pigs was significantly greater than that of bronchial isoproterenol. In dogs, the drug is more potent and selective to block the isoproterenol chronotropic response. In humans, taking 200mg of this product per day and taking 100mg of alanyl per day produce the same reduction in isoproterenol